Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:57:42.135Z.
Calculation as of: 2026-10-06T14:57:42.135Z.
Quote observation: 2026-10-06T14:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$996.75M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$992.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.17M
Price/OCF Ratio
72.19
TTM Avg
103.87
3Y Avg
103.87
5Y Avg
103.87
Market Cap
$1.01B
Price/OCF Ratio
N/A
TTM Avg
517.11
3Y Avg
517.11
5Y Avg
517.11
Market Cap
$1.02B
Price/OCF Ratio
11.93
TTM Avg
14.48
3Y Avg
14.58
5Y Avg
15.53
Market Cap
$1.03B
Price/OCF Ratio
15.90
TTM Avg
16.75
3Y Avg
16.75
5Y Avg
16.75
Market Cap
$943.53M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $996.75M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $992.49M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $992.21M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $988.17M | 72.19 | 103.87 | 103.87 | 103.87 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | N/A | 517.11 | 517.11 | 517.11 |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 78.34 | 28.91 | 23.78 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | 11.93 | 14.48 | 14.58 | 15.53 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 15.90 | 16.75 | 16.75 | 16.75 |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $943.53M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.05B | 24.69 | 16.06 | 17.84 | 17.84 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
